LKT Laboratories, Inc.

LY-2603618

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID L9704
CAS No. 911222-45-2
Chemical Name 1-[5-bromo-4-methyl-2-[[(2S)-morpholin-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea
Synonym Rabusertib



Formula $C_{18}H_{22}BrN_5O_3$
Formula Wt. 436.31
Melting Point
Purity ≥98%
Solubility 13mg/mL in DMSO, insoluble in water and ethanol

Store Temp -20˚C
Ship Temp Ambient

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
L9704	1 mg	$65.00
L9704	5 mg	$95.00
L9704	10 mg	$175.00
L9704	25 mg	$305.00

Description LY-2603618 is an inhibitor of checkpoint kinase (CHK) 1 that exhibits anticancer chemotherapeutic activity. In various animal models with tumor xenografts, this compound inhibits the S phase DNA damage checkpoint and increases DNA damage. In lung cancer cells, LY-2603618 induces G2/M phase cell cycle arrest and autophagy. LY-2603618 also enhances activity of other co-administered chemotherapeutics such as gemcitabine.

References

Barnard D, Diaz HB, Burke T, et al. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. Invest New Drugs. 2015 Nov 27. [Epub ahead of print]. PMID: 26612134.

Wang FZ, Fei HR, Cui YJ, et al. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Apoptosis. 2014 Sep;19(9):1389-98. PMID: 24928205.

King C, Diaz H, Barnard D, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26. PMID: 24114124.